546 results on '"Pittock, Sean"'
Search Results
2. Autoimmune and paraneoplastic neurological disorders
3. Contributors
4. Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial
5. Seizure-Related Falls and Near Falls in LGI1-IgG Autoimmune Encephalitis
6. Clinical and serological insights into paraneoplastic brachial amyotrophic diplegia
7. Network Meta-analysis of Ravulizumab and Alternative Interventions for the Treatment of Neuromyelitis Optica Spectrum Disorder
8. Acute Optic Neuropathy in Older Adults
9. Association of Cytokine Proteins with Disease Activity in Neuromyelitis Optica Spectrum Disorder Participants Receiving Inebilizumab Treatment (S32.005)
10. Indirect Treatment Comparison of Ravulizumab Versus Approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-Positive (AQP4-IgG+) Neuromyelitis Optica Spectrum Disorder (NMOSD) (P10-14.005)
11. Late Relapse After Prolonged Remission Post-autologous Hematopoietic Stem Cell Transplantation in Two Patients with AQP4-IgG+ Neuromyelitis Optica Spectrum Disorder (P11-14.001)
12. Isolated Nervous System Histiocytic Neoplasms: Clinical Manifestations, Treatment, and Outcomes (P4-5.018)
13. Residual Symptoms, Recovery & Predictors of Long-term Sequalae After Autoimmune Encephalitis (S4.003)
14. Identification of SKOR2 IgG as a Novel Biomarker of Paraneoplastic Neurologic Syndrome (N1.001)
15. Efficacy and Safety of Ravulizumab in Adults With Anti-Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder (AQP4+ NMOSD): Interim Analysis From the Ongoing Phase 3 CHAMPION-NMOSD Trial (S32.003)
16. Etiologies of Myelopathy in Uganda Based on Neuroimaging, Autoantibodies, and Next Generation Sequencing (S4.008)
17. Identification of Calcium Dysregulation in Immune-mediated Rippling Muscle Disease (P8-11.001)
18. CAMKV Autoimmune Paraneoplastic Encephalitis (N1.003)
19. Isolated Meningitis Is a Unique Clinical Phenotype of Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (P9-14.003)
20. Diagnostic Utility of MOG Antibody Testing in Cerebrospinal Fluid
21. Defining the CSF Cytokine and Chemokine Signature of Neurosarcoidosis (S38.009)
22. Investigating Radiological Lag and the Temporal Evolution of MRI Lesions Within the Same Attack in MOGAD (S32.008)
23. Evaluation of Glial Fibrillary Acidic Protein (GFAP) and Neurofilament Light Chain (NfL) Levels During Eculizumab and Ravulizumab Treatments in Aquaporin-4-Positive (AQP4+) Neuromyelitis Optica Spectrum Disorder (NMOSD) (S32.004)
24. Hearing Loss, Imbalance, and Diplopia in a 44-Year-Old Man
25. Constipation and Syncope
26. Non–Multiple Sclerosis Central Nervous System Inflammatory Disease
27. Neuromyelitis Optica
28. Immediate and sustained terminal complement inhibition with ravulizumab in patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder
29. Peripheral nervous system manifestations of MOG antibody associated disease
30. Cerebellar leptomeningeal enhancement: An imaging finding of rapidly progressive Purkinje cell cytoplasmic autoantibody type 1 paraneoplastic cerebellar syndrome
31. Efficacy and safety of ravulizumab in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: Outcomes from the phase 3 CHAMPION-NMOSD trial
32. Utility of the 2021 paraneoplastic neurologic syndromes diagnostic criteria
33. International MOGAD criteria
34. Intravenous ravulizumab in mechanically ventilated patients hospitalised with severe COVID-19: a phase 3, multicentre, open-label, randomised controlled trial
35. Microfibrillar-associated protein 4 as a potential marker of acute relapse in inflammatory demyelinating diseases of the central nervous system: Pathological and clinical aspects
36. CDR2 and CDR2L line blot performance in PCA-1/anti-Yo paraneoplastic autoimmunity
37. Timing and Predictors of T2-Lesion Resolution in Patients With Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease
38. Detection of High‐Risk Paraneoplastic Antibodies against TRIM9 and TRIM67 Proteins
39. Identification of SKOR2 IgG as a novel biomarker of paraneoplastic neurologic syndrome
40. Autoimmune Encephalitis
41. Paraneoplastic and Idiopathic Autoimmune Neurological Disorders Affecting the Central Nervous System and Autoimmune Dysautonomia
42. Frequency of demyelinating disease activity following immune checkpoint inhibitor cancer immunotherapy
43. Utility of Protein Microarrays for Detection of Classified and Novel Antibodies in Autoimmune Neurologic Disease
44. Visual Outcomes Following Plasma Exchange for Optic Neuritis: An International Multicenter Retrospective Analysis of 395 Optic Neuritis Attacks
45. Tenascin‐R Autoimmunity: Isolated Tremor Reversed with Immunotherapy
46. Do Early Relapses Predict the Risk of Long‐Term Relapsing Disease in an Adult and Paediatric Cohort with MOGAD?
47. Seizure characteristics and outcomes in patients with neurological conditions related to high‐risk paraneoplastic antibodies
48. Subacute Horizontal Diplopia, Jaw Dystonia, and Laryngospasm
49. Attack adjudication in neuromyelitis optica spectrum disorder: Substantiation of criteria by magnetic resonance imaging and biomarkers in N-MOmentum
50. Paraneoplastic Neurologic Disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.